Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247175 | PMC |
| http://dx.doi.org/10.1373/clinchem.2013.211045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global trends in the application of droplet digital PCR technology in the field of infectious disease pathogen diagnosis: A bibliometric analysis from 2012 to 2023.
Diagn Microbiol Infect Dis
November 2024
Beijing Ditan Hospital, Capital Medical University, Beijing, China; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China. Electronic address:
Background: This study discusses the development trends and current applications of digital droplet PCR technology in pathogen diagnostics.
Methods: A bibliometric analysis was conducted by retrieving droplet digital pcr related articles published between January 1,2012 to December31, 2023, from the Web of Science Core Collection.
Results: A total of 3,513 authors from 66 countries published 508 research papers across 203 academic institutions.
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.
Br J Haematol
November 2024
AOU Città della Salute e della Scienza di Torino-Ematologia U, Turin, Italy.
This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m on days 1-2), rituximab (375 mg/m intravenously on day 1) and bortezomib (1.3 mg/m sc on days 1, 8, 15, 22) every 28 days for six cycles in 38 symptomatic patients with relapsed/refractory Waldenstrom macroglobulinaemia (RR-WM). Moreover, MYD88 and CXCR4 mutations were tested by droplet digital polymerase chain reaction (ddPCR) both at baseline and at the end of treatment in 21 patients.
View Article and Find Full Text PDFEvaluation of PCR-enhancing approaches to reduce inhibition in wastewater samples and enhance viral load measurements.
Sci Total Environ
December 2024
Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou, 15771 Athens, Greece. Electronic address:
Molecular-based assays are the most commonly used methods for the detection and quantification of viruses in wastewater. The variety of inhibitory substances present in the complex matrix of wastewater hinders downstream analysis and often leads to false negative results and underestimation of viral load. The development of robust and inhibitor-tolerant detection methods is necessary in the context of wastewater-based epidemiology, a valuable tool that has gained further importance since the emergence of the Covid-19 pandemic.
View Article and Find Full Text PDFAn Improved Bulk DNA Extraction Method for Detection of (Lepidoptera: Noctuidae) Using Real-Time PCR.
Insects
August 2024
Department of Agricultural Biology, Colorado State University, Fort Collins, CO 80523-1177, USA.
is among the most problematic agricultural pests worldwide due to its polyphagy and ability to evolve pesticide resistance. Molecular detection methods for have been developed to track its spread, as such methods allow for rapid and accurate differentiation from the native sibling species . Droplet digital PCR (ddPCR) is a preferred method for bulk screening due to its accuracy and tolerance to PCR inhibitors; however, real-time PCR is less expensive and more widely available in molecular labs.
View Article and Find Full Text PDFPhase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Cancer Med
July 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Mouse double minute-2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes.
Methods: This phase 1 study assessed the safety and efficacy of different dosing regimens of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine (AZA) in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Results: Seventy-four patients (monotherapy, n = 57; milademetan-AZA combination, n = 17) were treated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!